However, a recent meta-analysis focusing on studies comparing ibrutinib to second-generation BTK inhibitors revealed similar risks of coronary artery disease (CAD), ventricular tachycardia, sudden cardiac death, hypertension, and treatment discontinuation due to cardiac events between ibrutinib and second generation BTKi [28]. Here, IBTK is linked to hypertensive disorder.